⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OVID News
Ovid Therapeutics Inc. Common Stock
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
globenewswire.com
OVID
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
globenewswire.com
OVID
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
globenewswire.com
OVID
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
globenewswire.com
OVID
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
globenewswire.com
OVID